Abbott gains access to BG Medicine biomarker

Kaitlyn Dmyterko | | Health Imaging | Practice Management
Abbott and BG Medicine will partner to develop galectin-3, a protein that advances cardiac fibrosis, to better understand the evolution of heart failure.

The Abbott Park, Ill.-based company said the biomarker will be developed for its i1000SR and i2000SR Architect Immunochemistry instrument platforms.

Under the terms of agreement, Waltham, Mass.-based BG Medicine will grant rights to Abbott for its intellectual property of galectin-3. The companies have not yet released the financial ramifications of the agreement.

Kaitlyn Dmyterko

Related Content

New protocol addresses contrast allergies in patients with suspected stroke
Do large language models help or hinder workflows related to radiology reports?
Hospital creates 'virtual reality technologist' role to support patients during interventional procedures
Telehealth visits not to blame for uptick in imaging orders, study shows
Up to half of medical organizations either already using or preparing to implement AI
Warning: Sidelined reactor could trigger medical isotope shortage

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.